Proposed rule: Expect new telehealth and controlled substance Rx requirements

Why This Topic Matters

These proposed rules could alter telehealth prescribing workflows, treatment continuity, and compliance planning for controlled substances and opioid use disorder care. Organizations that manage telehealth services or substance use disorder treatment need to monitor the final federal requirements.

Article Sections

1. SAMHSA plans to make two waivers permanent

   This section covers proposed federal changes affecting opioid treatment program standards and telehealth-related treatment flexibilities. It discusses the broader policy context for medication-assisted treatment under SAMHSA oversight.

2. DEA intends to end some waivers

   This section summarizes DEA proposed rules affecting telemedicine prescribing of controlled substances. It focuses on the general categories of prescribing relationships and medication types addressed by the agency.

3. Telemedicine organization expresses concern

   This section presents a professional association’s reaction to the proposed DEA rules. It highlights stakeholder concerns and support for selected transition provisions.

4. Resources

   This section lists related federal and professional resources for readers who want to review the source material and agency announcements.